Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nadolol + isosorbide mononitrate
- Development stage
- Phase 4
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of nadolol (a non-selective beta-adrenergic antagonist) and isosorbide mononitrate (a nitrate vasodilator). This combination is primarily used for the prevention of recurrent bleeding in patients with cirrhosis and esophageal varices. The therapy works by reducing portal hypertension through complementary mechanisms - nadolol reduces cardiac output and inhibits renin release by blocking beta-adrenergic receptors, while isosorbide mononitrate causes vasodilation, particularly in the venous system, by activating the nitric oxide-cGMP pathway.
02
Targets
ADRB1 (β1)ADRB2 (β2)sGC (Soluble Guanylyl Cyclase)
Beyond the preview
Go deeper on nadolol + isosorbide mononitrate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nadolol + isosorbide mononitrate.